Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $30.6 million.

  • Amicus Therapeutics' Change in Accured Expenses rose 31684.37% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.6 million, marking a year-over-year increase of 126839.78%. This contributed to the annual value of -$16.5 million for FY2024, which is 13358.06% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Change in Accured Expenses of $30.6 million as of Q3 2025, which was up 31684.37% from $10.4 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Change in Accured Expenses peaked at $37.2 million during Q2 2022, and registered a low of -$40.2 million during Q1 2021.
  • Over the past 5 years, Amicus Therapeutics' median Change in Accured Expenses value was $6.4 million (recorded in 2021), while the average stood at $4.1 million.
  • Per our database at Business Quant, Amicus Therapeutics' Change in Accured Expenses skyrocketed by 120426.83% in 2021 and then crashed by 3390416.67% in 2024.
  • Amicus Therapeutics' Change in Accured Expenses (Quarter) stood at $29.5 million in 2021, then tumbled by 207.95% to -$31.8 million in 2022, then soared by 125.42% to $8.1 million in 2023, then plummeted by 162.23% to -$5.0 million in 2024, then soared by 708.04% to $30.6 million in 2025.
  • Its Change in Accured Expenses was $30.6 million in Q3 2025, compared to $10.4 million in Q2 2025 and $3.6 million in Q1 2025.